Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Tymara Berry, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138818

Published: 2020

Journal Articles

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Guru Subramanian Guru Murthy, MD, Soyoung Kim, Zhen-Huan Hu, MPH, Noel Estrada-Merly, MS, Ryotaro Nakamura, MD, Betul Oran, MDMS, Bart L. Scott, MD, Ronald Sobecks, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-140647

Published: 2020

Journal Articles

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136828

Published: 2020

Journal Articles

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Tymara Berry, MD, Faye Feller, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138905

Published: 2020

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Faye Feller, MD, Fei Huang, PhD, Aleksandra Rizo, MD PhD, Libo Sun, PhD, Ying Wan, PhD, Alessandro M. Vannucchi, MD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138823

Published: 2020

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Betul Oran, MDMS, Kwang Woo Ahn, PhD, Caitrin Fretham, Mithun Vinod Shah, MD PhD, Ryotaro Nakamura, MD, Bart L. Scott, MD, Ronald Sobecks, MD, Uday Popat, MD, Wael Saber, MD MS

Blood (2019) 134 (Supplement_1): 253.

https://doi.org/10.1182/blood-2019-121970

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Kelda Gardner, PA-C, Megan Othus, PhD, Carole M. Shaw, BA, Pamela S. Becker, MD PhD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 5093.

https://doi.org/10.1182/blood-2019-130965

Published: 2019

Journal Articles

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Kelda Gardner, PA-C, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Anna B. Halpern, MD, Carole M. Shaw, BA, Jacob Appelbaum, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 5094.

https://doi.org/10.1182/blood-2019-131280

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban B. Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1317.

https://doi.org/10.1182/blood-2019-124586

Published: 2019

Journal Articles

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1323.

https://doi.org/10.1182/blood-2019-123605

Published: 2019

Journal Articles

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Genevieve Alcorn, Mary-Elizabeth M. Percival, MD, Emily M Huebner, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Vivian G. Oehler, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1364.

https://doi.org/10.1182/blood-2019-123542

Published: 2019

Journal Articles

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

Srdan Verstovsek, MD PhD, Bart L. Scott, MD, Jason A Taylor, MD PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1674.

https://doi.org/10.1182/blood-2019-127609

Published: 2019

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

NARROW

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only